Guard Therapeutics International Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 5

Employees

  • Latest Deal Type
  • M&A

Guard Therapeutics International General Information

Description

Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.

Contact Information

Formerly Known As
A1M-Pharma
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Nybrogatan 34, 2nd floor
  • 114 39 Stockholm
  • Sweden
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Disruptive Pharma
Vertical(s)
Corporate Office
  • Nybrogatan 34, 2nd floor
  • 114 39 Stockholm
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Guard Therapeutics International Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 27-Jul-2026 Completed Generating Revenue
6. 2PO 17-Jun-2024 Completed Generating Revenue
5. 2PO 20-Oct-2021 Cancelled Generating Revenue
4. PIPE 17-Jun-2019 Completed Generating Revenue
3. IPO 03-Apr-2013 Completed Generating Revenue
2. Early Stage VC Completed Startup
1. Accelerator/Incubator Completed Startup
To view Guard Therapeutics International’s complete valuation and funding history, request access »

Guard Therapeutics International Patents

Guard Therapeutics International Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024219294-A1 Alpha-1-microglobulin derived peptide fragments and uses thereof Pending 08-Feb-2023
EP-4661893-A1 Alpha-1-microglobulin derived peptide fragments and uses thereof Pending 08-Feb-2023
WO-2024165674-A1 Alpha-1-microglobulin derived peptide fragments and uses thereof Inactive 08-Feb-2023
JP-2026507475-A Alpha-1-microglobulin-derived peptide fragments and uses thereof Pending 08-Feb-2023
JP-2021501750-A Use of alpha-1-microglobulin for bone marrow cell protection Inactive 03-Nov-2017 A61K38/1722
To view Guard Therapeutics International’s complete patent history, request access »

Guard Therapeutics International Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Guard Therapeutics International Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Industrifonden Venture Capital Minority
LU Ventures (Lund) Corporate Venture Capital Minority
M2 Asset Management Asset Manager Minority
SmiLe Incubator Accelerator/Incubator
Unionen Corporation Minority
To view Guard Therapeutics International’s complete investors history, request access »

Guard Therapeutics International Investments & Acquisitions (2)

Guard Therapeutics International’s most recent deal was a Reverse Merger with Disruptive Materials. The deal was made on 11-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Disruptive Materials 11-Jun-2026 Reverse Merger Specialty Chemicals
ImmuneBiotech 16-Feb-2018 Angel (individual) Drug Discovery
To view Guard Therapeutics International’s complete investments and acquisitions history, request access »

Guard Therapeutics International ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Guard Therapeutics International’s complete esg history, request access »

Guard Therapeutics International FAQs

  • When was Guard Therapeutics International founded?

    Guard Therapeutics International was founded in 2008.

  • Where is Guard Therapeutics International headquartered?

    Guard Therapeutics International is headquartered in Stockholm, Sweden.

  • What is the size of Guard Therapeutics International?

    Guard Therapeutics International has 5 total employees.

  • What industry is Guard Therapeutics International in?

    Guard Therapeutics International’s primary industry is Drug Discovery.

  • Is Guard Therapeutics International a private or public company?

    Guard Therapeutics International is a Private company.

  • What is Guard Therapeutics International’s current revenue?

    The current revenue for Guard Therapeutics International is .

  • How much funding has Guard Therapeutics International raised over time?

    Guard Therapeutics International has raised $2.86M.

  • Who are Guard Therapeutics International’s investors?

    Industrifonden, LU Ventures (Lund), M2 Asset Management, SmiLe Incubator, and Unionen have invested in Guard Therapeutics International.

  • When was Guard Therapeutics International acquired?

    Guard Therapeutics International was acquired on 27-Jul-2026.

  • Who acquired Guard Therapeutics International?

    Guard Therapeutics International was acquired by Disruptive Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process